Floatz logo

Pegfilgrastim bmez

Chemotherapy-induced Neutropenia

Sandozprotein_peptidePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Chemotherapy-induced Neutropenia cohort.

Asset / SponsorPhaseRating
PEGFILGRASTIM
BeyondSpring Pharmaceuticals Inc.
Phase 3BBB
Inno-206
BeyondSpring Pharmaceuticals Inc.
Phase 3BB
EMPEGFILGRASTIM
Biocad
Phase 3BB
FILGRASTIM
Ankara Etlik City Hospital
Phase 3BB
Docetaxel
BeyondSpring Pharmaceuticals Inc.
Phase 3BB

View all 25 →

Same molecule, other indications

Pegfilgrastim bmez is also rated in:

chemotherapy-induced toxicityDormant
B
Indicative ·
60 / 100
View asset →
breast neoplasmDormant
CCC
Indicative ·
54 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →